Free tool
FAERS Monitor: Narcan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208411 or its brand name (Narcan, Naloxone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
4,866
Serious
3,463
71% of reports
Hospitalization
1,880
Death reported
743
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea389
- fatigue365
- pain347
- death301
- vomiting291
- diarrhoea272
- dyspnoea248
- off label use245
- toxicity to various agents230
- drug ineffective223
- headache219
- overdose213
- fall206
- pneumonia183
- anxiety171
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 12 |
| 2006 | 9 |
| 2007 | 18 |
| 2008 | 33 |
| 2009 | 24 |
| 2010 | 37 |
| 2011 | 39 |
| 2012 | 37 |
| 2013 | 21 |
| 2014 | 43 |
| 2015 | 55 |
| 2016 | 186 |
| 2017 | 110 |
| 2018 | 245 |
| 2019 | 330 |
| 2020 | 644 |
| 2021 | 508 |
| 2022 | 477 |
| 2023 | 521 |
| 2024 | 538 |
| 2025 | 608 |
| 2026 | 361 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,293 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxicity to various agentsSignal | 230 | 5.9 | 5.2 | 938 |
| overdoseSignal | 213 | 4.3 | 3.7 | 535 |
| fallSignal | 206 | 2.7 | 2.3 | 218 |
| vomitingSignal | 291 | 2.7 | 2.4 | 311 |
| anxietySignal | 171 | 2.6 | 2.2 | 169 |
| pneumoniaSignal | 183 | 2.4 | 2.1 | 157 |
| painSignal | 347 | 2.4 | 2.2 | 303 |
| nauseaSignal | 389 | 2.1 | 1.9 | 239 |
| fatigueSignal | 365 | 2.0 | 1.8 | 196 |
| dyspnoea | 248 | 1.9 | 1.7 | 107 |
| diarrhoea | 272 | 1.8 | 1.6 | 103 |
| death | 301 | 1.5 | 1.4 | 54 |
| headache | 219 | 1.5 | 1.3 | 38 |
| off label use | 245 | 1.2 | 1.1 | 9 |
| drug ineffective | 223 | 0.7 | 0.6 | 23 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.